文献速递角膜与眼表疾病

二氟泼尼酯治疗前巩膜炎的有效性

Effectiveness of Difluprednate for the Treatment of Anterior Scleritis.
PubMed 文献 · Am J Ophthalmol · 2021-09-20

PURPOSE: To describe the effectiveness and side effect profile of difluprednate therapy in a series of patients with anterior scleritis. DESIGN: Retrospective, interventional case series.…

要点

  • 需监测眼压升高(9眼)和视力下降(4眼)等副作用。

核心结论

  • 二氟泼尼酯单药可能有效治疗非感染性前巩膜炎,且副作用可耐受。

主要发现

  • 9眼出现眼压升高,4眼视力下降≥2行,其中1眼因白内障进展,1眼行白内障手术。

关键数值与推荐

  • 主要结局为巩膜炎临床消退,次要结局包括视力下降≥2行、晶状体状态改变或白内障手术、眼压≥24 mm Hg。

临床怎么用

  • 对于非感染性前巩膜炎,可考虑二氟泼尼酯单药治疗,初始剂量≥每日4次可能提高消退率。
  • 治疗期间应监测眼压、视力及晶状体状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the effectiveness and side effect profile of difluprednate therapy in a series of patients with anterior scleritis. DESIGN: Retrospective, interventional case series. METHODS: Data collected from all patients with anterior scleritis who used difluprednate as a single treatment agent from January 1, 2018, to January 1, 2020, including demographics, scleritis type, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, best-corrected visual acuity (BCVA), and lens status. The primary outcome was clinical resolution of scleritis. Secondary outcomes included BCVA loss ≥2 lines, change in lens status or cataract surgery, and IOP ≥24 mm Hg. RESULTS: Twenty-five patients (35 eyes) were analyzed. The median age was 60 years (range 13-78); 60% were female; 64% were White. Forty percent had bilateral disease, and 44% of patients had an associated systemic disease. The majority of eyes (66%) had diffuse anterior scleritis. Eighty-three percent of eyes achieved resolution of scleritis, with a median time of resolution of 6 weeks. Eyes treated with an initial dose of ≥4 times daily were more likely to achieve disease resolution (hazard ratio [HR] = 3.43, 95% confidence interval [CI] 1.19, 9.88, P = .02). Nine eyes had IOP elevation. Four eyes lost ≥2 lines of BCVA, and 1 due to cataract progression. One eye underwent cataract surgery. CONCLUSIONS: Difluprednate alone may effectively treat non-infectious anterior scleritis with a tolerable side effect profile.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Liberman P, Burkholder BM, Thorne JE, et al. Effectiveness of Difluprednate for the Treatment of Anterior Scleritis. Am J Ophthalmol. 2021. PMID: 34547279. doi:10.1016/j.ajo.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。